587 related articles for article (PubMed ID: 15652653)
1. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
[TBL] [Abstract][Full Text] [Related]
2. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
[TBL] [Abstract][Full Text] [Related]
3. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M
Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
[TBL] [Abstract][Full Text] [Related]
5. Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions.
Klose J; Fechner K; Beyermann M; Krause E; Wendt N; Bienert M; Rudolph R; Rothemund S
Biochemistry; 2005 Feb; 44(5):1614-23. PubMed ID: 15683245
[TBL] [Abstract][Full Text] [Related]
6. Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.
Jahn O; Tezval H; van Werven L; Eckart K; Spiess J
Neuropharmacology; 2004 Aug; 47(2):233-42. PubMed ID: 15223302
[TBL] [Abstract][Full Text] [Related]
7. Molecular cloning and functional expression of the mouse CRF2(a) receptor splice variant.
Dautzenberg FM; Higelin J; Wille S; Brauns O
Regul Pept; 2004 Sep; 121(1-3):89-97. PubMed ID: 15256278
[TBL] [Abstract][Full Text] [Related]
8. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.
Beyermann M; Heinrich N; Fechner K; Furkert J; Zhang W; Kraetke O; Bienert M; Berger H
Br J Pharmacol; 2007 Jul; 151(6):851-9. PubMed ID: 17533422
[TBL] [Abstract][Full Text] [Related]
9. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.
Zorrilla EP; Reinhardt LE; Valdez GR; Inoue K; Rivier JE; Vale WW; Koob GF
J Pharmacol Exp Ther; 2004 Sep; 310(3):1027-34. PubMed ID: 15115804
[TBL] [Abstract][Full Text] [Related]
10. Endogenous expression and in vitro study of CRF-related peptides and CRF receptors in the rat gastric antrum.
Porcher C; Peinnequin A; Pellissier S; Meregnani J; Sinniger V; Canini F; Bonaz B
Peptides; 2006 Jun; 27(6):1464-75. PubMed ID: 16337313
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland.
Okada R; Miller MF; Yamamoto K; De Groef B; Denver RJ; Kikuyama S
Gen Comp Endocrinol; 2007 Feb; 150(3):437-44. PubMed ID: 17188689
[TBL] [Abstract][Full Text] [Related]
12. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
Perrin MH; Sutton SW; Cervini LA; Rivier JE; Vale WW
J Pharmacol Exp Ther; 1999 Feb; 288(2):729-34. PubMed ID: 9918582
[TBL] [Abstract][Full Text] [Related]
13. Functional CRF receptors in BON cells stimulate serotonin release.
von Mentzer B; Murata Y; Ahlstedt I; Lindström E; Martínez V
Biochem Pharmacol; 2007 Mar; 73(6):805-13. PubMed ID: 17184738
[TBL] [Abstract][Full Text] [Related]
14. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
[TBL] [Abstract][Full Text] [Related]
15. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
Dautzenberg FM; Wille S
Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
[TBL] [Abstract][Full Text] [Related]
16. Expression and effects of metabotropic CRF1 and CRF2 receptors in rat small intestine.
Porcher C; Juhem A; Peinnequin A; Sinniger V; Bonaz B
Am J Physiol Gastrointest Liver Physiol; 2005 May; 288(5):G1091-103. PubMed ID: 15637181
[TBL] [Abstract][Full Text] [Related]
17. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system.
Hashimoto K; Nishiyama M; Tanaka Y; Noguchi T; Asaba K; Hossein PN; Nishioka T; Makino S
Peptides; 2004 Oct; 25(10):1711-21. PubMed ID: 15476938
[TBL] [Abstract][Full Text] [Related]
18. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain.
Primus RJ; Yevich E; Baltazar C; Gallager DW
Neuropsychopharmacology; 1997 Nov; 17(5):308-16. PubMed ID: 9348546
[TBL] [Abstract][Full Text] [Related]
19. Corticotropin-releasing factor, urocortin 1, and their receptors in the mouse spinal cord.
Korosi A; Kozicz T; Richter J; Veening JG; Olivier B; Roubos EW
J Comp Neurol; 2007 Jun; 502(6):973-89. PubMed ID: 17444496
[TBL] [Abstract][Full Text] [Related]
20. Urocortins and the regulation of gastrointestinal motor function and visceral pain.
Martinez V; Wang L; Million M; Rivier J; Taché Y
Peptides; 2004 Oct; 25(10):1733-44. PubMed ID: 15476940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
